Abstract
Prostate cancer (PCa) is the second most prevalent neoplasm amongst men. Treatments grant survival, however they do not always cure; making it appropriate the adoption of adjuvant therapies, such as the passive immunotherapy with the use of tumor-specific monoclonal antibodies (mAbs). The mAbs originated from conventional immunization recognizes immunodominants epitopes. The subtractive i…